Condition (MeSH)
Tibial Plateau Fractures
ClinicalTrials.gov lists 28 trials for Tibial Plateau Fractures or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with Tibial Plateau Fractures itself; the rest are tagged with a narrower condition beneath it.
When did Tibial Plateau Fractures trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 3 |
| 2022 | 5 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 1 |
| 2015 | 1 |
| 2013 | 2 |
| 2011 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tibial Plateau Fractures trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 3 | 1 |
| Phase 4 | 2 |
| Not applicable | 13 |
| Observational | 8 |
How many Tibial Plateau Fractures trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 4 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 2 |
| Completed | 11 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Tibial Plateau Fractures? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| +/- Bupivacaine HCl | 2 |
| Duloxetine | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Nitroglycerin Ointment 2% | 1 |
| CRYOTHERAPY | 1 |
| Multimodal injections | 1 |
| Bupivacain 25% (Erector Spinae Plane Block) | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tibial Plateau Fractures trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| CARDIAC FAILURE CONGESTIVE | 2 | 1 |
| FALL | 2 | 1 |
| INFECTION | 2 | 1 |
| LOSS OF ANATOMICAL ALIGNMENT AFTER FRACTURE REDUCTION | 2 | 1 |
| AORTIC VALVE STENOSIS | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Tibial Plateau Fractures? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Surgical fixation methods for tibial plateau fractures. | The Cochrane database of systematic reviews | 2024 | Yes |
| Primary total knee arthroplasty in tibial plateau fractures: Literature review and our institutional experience. | Injury | 2023 | Yes |
| Immediate Weight-Bearing after tibial plateau fractures Enhances spatiotemporal gait parameters and minimize fall Risk: A randomized clinical trial. | Journal of biomechanics | 2025 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, prevalence, rare-disease identity, and sub-conditions in mesh.